Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Emergent BioSolutions

< Previous 1 2 3 Next >
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports First Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
From Emergent BioSolutions
Via GlobeNewswire
Tickers BLCO EBS
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS LQDA
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces CEO Transition
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.